These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 29154902

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE.
    Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
    Apaijai N, Pintana H, Chattipakorn SC, Chattipakorn N.
    Br J Pharmacol; 2013 Jul; 169(5):1048-57. PubMed ID: 23488656
    [Abstract] [Full Text] [Related]

  • 5. Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model.
    Omar BA, Vikman J, Winzell MS, Voss U, Ekblad E, Foley JE, Ahrén B.
    Diabetologia; 2013 Aug; 56(8):1752-60. PubMed ID: 23636640
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
    Ávila Dde L, Araújo GR, Silva M, Miranda PH, Diniz MF, Pedrosa ML, Silva ME, de Lima WG, Costa DC.
    Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
    Inthachai T, Lekawanvijit S, Kumfu S, Apaijai N, Pongkan W, Chattipakorn SC, Chattipakorn N.
    Exp Physiol; 2015 Jun; 100(6):667-79. PubMed ID: 25823534
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat.
    Vavrinec P, Henning RH, Landheer SW, Wang Y, Deelman LE, Dokkum RP, Buikema H.
    Curr Vasc Pharmacol; 2014 Jun; 12(6):836-44. PubMed ID: 24066937
    [Abstract] [Full Text] [Related]

  • 16. Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
    Miyagawa K, Kondo T, Goto R, Matsuyama R, Ono K, Kitano S, Kawasaki S, Igata M, Kawashima J, Matsumura T, Motoshima H, Araki E.
    Cardiovasc Diabetol; 2013 Nov 04; 12():160. PubMed ID: 24188631
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue.
    Kos K, Baker AR, Jernas M, Harte AL, Clapham JC, O'Hare JP, Carlsson L, Kumar S, McTernan PG.
    Diabetes Obes Metab; 2009 Apr 04; 11(4):285-92. PubMed ID: 19175376
    [Abstract] [Full Text] [Related]

  • 20. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K, Hara A, Fujitani Y, Uchida T, Komiya K, Tamaki M, Abe H, Ogihara T, Kanazawa A, Kawamori R, Watada H.
    Biochem Biophys Res Commun; 2013 Nov 01; 440(4):570-5. PubMed ID: 24103756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.